NASDAQ:BIOR Biora Therapeutics (BIOR) Stock Forecast, Price & News $4.49 +0.07 (+1.58%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$4.41▼$4.7850-Day Range$2.31▼$4.8552-Week Range$1.95▼$28.75Volume124,135 shsAverage Volume1.46 million shsMarket Capitalization$53.25 millionP/E RatioN/ADividend YieldN/APrice Target$3,750.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biora Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside83,418.9% Upside$3,750.00 Price TargetShort InterestHealthy3.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.69) to ($4.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector610th out of 983 stocksPharmaceutical Preparations Industry302nd out of 486 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $3,750.00, Biora Therapeutics has a forecasted upside of 83,418.9% from its current price of $4.49.Amount of Analyst CoverageBiora Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.45% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biora Therapeutics has recently decreased by 7.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOR. Previous Next 0.6 News and Social Media Coverage Search Interest18 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.24% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.13% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($6.69) to ($4.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Biora Therapeutics (NASDAQ:BIOR) StockBiora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Read More Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOR Stock News HeadlinesMay 20, 2023 | americanbankingnews.comHC Wainwright Brokers Boost Earnings Estimates for Biora Therapeutics, Inc. (NASDAQ:BIOR)May 17, 2023 | finance.yahoo.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2023 Earnings Call TranscriptJune 2, 2023 | Behind the Markets (Ad)⚡ 2,467% Return on Israeli Laser Company?This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.May 17, 2023 | americanbankingnews.comBiora Therapeutics, Inc. Forecasted to Post Q2 2023 Earnings of ($1.60) Per Share (NASDAQ:BIOR)May 16, 2023 | finance.yahoo.comQ1 2023 Biora Therapeutics Inc Earnings CallMay 16, 2023 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | benzinga.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | msn.comRecap: Biora Therapeutics Q1 EarningsJune 2, 2023 | Behind the Markets (Ad)⚡ 2,467% Return on Israeli Laser Company?This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.May 15, 2023 | finance.yahoo.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 14, 2023 | americanbankingnews.comBiora Therapeutics (BIOR) Scheduled to Post Quarterly Earnings on MondayMay 12, 2023 | msn.comEarnings Preview: Biora TherapeuticsMay 8, 2023 | finance.yahoo.comBiora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate UpdateMay 1, 2023 | finance.yahoo.comBiora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical OfficerApril 26, 2023 | forbes.comA Recession Looks More Likely, And Google And Tesla CEO’s Both Praise And Raise Concerns About AI - Forbes AI Newsletter April 22ndApril 22, 2023 | americanbankingnews.comHorizon Therapeutics Public (NASDAQ:HZNP) & Biora Therapeutics (NASDAQ:BIOR) Head-To-Head SurveyApril 20, 2023 | finance.yahoo.comBiora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate ConferenceApril 5, 2023 | finance.yahoo.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2022 Earnings Call TranscriptApril 1, 2023 | benzinga.comBiora Therapeutics Stock (NASDAQ:BIOR), DividendsMarch 31, 2023 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial ResultsMarch 31, 2023 | msn.comBiora Therapeutics Earnings Perspective: Return On Invested CapitalMarch 30, 2023 | finance.yahoo.comBiora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial ResultsMarch 29, 2023 | benzinga.comEarnings Preview For Biora TherapeuticsMarch 29, 2023 | americanbankingnews.comBiora Therapeutics (BIOR) to Release Quarterly Earnings on ThursdayMarch 23, 2023 | finance.yahoo.comBiora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate UpdateMarch 1, 2023 | msn.comWhat Does Biora Therapeutics' Debt Look Like?February 23, 2023 | finance.yahoo.comBiora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor AgonistSee More Headlines BIOR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOR Company Calendar Today6/02/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOR CUSIPN/A CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees642Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3,750.00 High Stock Price Forecast$3,750.00 Low Stock Price Forecast$3,750.00 Forecasted Upside/Downside+82,317.6%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($4.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,160,000.00 Net Margins-20,895.00% Pretax Margin-26,100.50% Return on EquityN/A Return on Assets-84.03% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.48 Sales & Book Value Annual Sales$310,000.00 Price / Sales174.07 Cash FlowN/A Price / Cash FlowN/A Book Value($8.85) per share Price / Book-0.51Miscellaneous Outstanding Shares11,860,000Free Float8,154,000Market Cap$53.96 million OptionableOptionable Beta1.16 Key ExecutivesMr. Aditya P. Mohanty M.B.A. (Age 56)CEO & Director Comp: $383.76kMr. Eric d'Esparbes (Age 55)Chief Financial Officer Comp: $619.3kMr. Clarke Neumann J.D. (Age 59)Gen. Counsel & Sec. Comp: $712.02kEric FoxVP of Fin. & Accounting & TreasurerMr. Troy Seelye (Age 59)Chief Information Officer Mr. George Gianakopoulos (Age 62)Sr. VP of Sales Ms. Robyn HattonHead of HRMr. Kevin Howe Ph.D.Sr. VP of Strategic OperationsDr. Sharat Singh Ph.D. (Age 64)Head of Research Dr. Paul Shabram M.B.A.Head of Technical OperationsMore ExecutivesKey CompetitorsAnebulo PharmaceuticalsNASDAQ:ANEBPraxis Precision MedicinesNASDAQ:PRAXEnochian BiosciencesNASDAQ:ENOBHCW BiologicsNASDAQ:HCWBViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCSold 1,058,283 shares on 5/16/2023Ownership: 0.372%Susquehanna International Group LLPSold 23,200 shares on 5/16/2023Ownership: 0.000%State Street CorpSold 421,774 shares on 5/16/2023Ownership: 0.148%Jane Street Group LLCSold 20,800 shares on 5/16/2023Ownership: 0.000%Schonfeld Strategic Advisors LLCBought 42,500 shares on 5/15/2023Ownership: 0.358%View All Insider TransactionsView All Institutional Transactions BIOR Stock - Frequently Asked Questions What is Biora Therapeutics' stock price forecast for 2023? 0 equities research analysts have issued 1 year target prices for Biora Therapeutics' shares. Their BIOR share price forecasts range from $3,750.00 to $3,750.00. On average, they expect the company's share price to reach $3,750.00 in the next twelve months. This suggests a possible upside of 82,317.6% from the stock's current price. View analysts price targets for BIOR or view top-rated stocks among Wall Street analysts. How have BIOR shares performed in 2023? Biora Therapeutics' stock was trading at $82.3125 at the start of the year. Since then, BIOR stock has decreased by 94.5% and is now trading at $4.55. View the best growth stocks for 2023 here. Are investors shorting Biora Therapeutics? Biora Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 390,700 shares, a drop of 7.7% from the April 30th total of 423,100 shares. Based on an average daily trading volume, of 142,000 shares, the days-to-cover ratio is currently 2.8 days. Currently, 3.5% of the shares of the company are sold short. View Biora Therapeutics' Short Interest. When is Biora Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our BIOR earnings forecast. When did Biora Therapeutics' stock split? Biora Therapeutics shares reverse split on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Biora Therapeutics' stock symbol? Biora Therapeutics trades on the NASDAQ under the ticker symbol "BIOR." Who are Biora Therapeutics' major shareholders? Biora Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.55%), Simplex Trading LLC (0.00%), Geode Capital Management LLC (0.37%), Schonfeld Strategic Advisors LLC (0.36%), Susquehanna International Group LLP (0.00%) and Group One Trading L.P. (0.00%). View institutional ownership trends. How do I buy shares of Biora Therapeutics? Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biora Therapeutics' stock price today? One share of BIOR stock can currently be purchased for approximately $4.55. How much money does Biora Therapeutics make? Biora Therapeutics (NASDAQ:BIOR) has a market capitalization of $53.96 million and generates $310,000.00 in revenue each year. The company earns $-38,160,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis. How many employees does Biora Therapeutics have? The company employs 642 workers across the globe. How can I contact Biora Therapeutics? Biora Therapeutics' mailing address is 4330 La Jolla Village Dr Ste 200, San Diego, California 92122. The official website for the company is www.bioratherapeutics.com. The company can be reached via phone at 833-727-2841 or via email at ir@progenity.com. This page (NASDAQ:BIOR) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.